| A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseNCT06283966 · Athens, Alabama | Phase 3 | 235 |
| Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinNCT06677060 · Birmingham, Alabama | Phase 3 | 198 |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionNCT06307652 · Alexander City, Alabama | Phase 3 | 166 |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · Birmingham, Alabama | Phase 3 | 127 |
| A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117 · Fairhope, Alabama | Phase 3 | 118 |
| Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With AsthmaNCT06307665 · Anchorage, Alaska | Phase 3 | 115 |
| Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2NCT07431281 · Birmingham, Alabama | Phase 3 | 92 |
| A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseNCT07082738 · Birmingham, Alabama | Phase 2 | 86 |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647 · Mobile, Alabama | Phase 3 | 77 |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)NCT06692738 · Tucson, Arizona | Phase 3 | 77 |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)NCT06878261 · Cullman, Alabama | Phase 3 | 74 |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)NCT06883305 · Foley, Alabama | Phase 3 | 73 |
| Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)NCT07044336 · Tucson, Arizona | Phase 3 | 69 |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)NCT06103864 · Daphne, Alabama | Phase 3 | 67 |
| A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusNCT07662213 · Birmingham, Alabama | Phase 3 | 64 |
| Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsNCT06357533 · Anchorage, Alaska | Phase 3 | 63 |
| Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled CorticosteroidsNCT06932263 · Bakersfield, California | Phase 2 | 63 |
| DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerNCT06989112 · Tucson, Arizona | Phase 3 | 62 |
| Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerNCT06380751 · Gilbert, Arizona | Phase 3 | 60 |
| A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsNCT06549595 · Huntsville, Alabama | Phase 3 | 59 |
| A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerNCT06764875 · Anchorage, Alaska | Phase 3 | 59 |
| A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DMNCT07667803 · Birmingham, Alabama | Phase 3 | 56 |
| Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic AlterationsNCT07291037 · Chandler, Arizona | Phase 3 | 51 |
| A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)NCT07391657 · Gilbert, Arizona | Phase 3 | 51 |
| Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerNCT06467357 · Scottsdale, Arizona | Phase 3 | 48 |
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationNCT06952803 · Phoenix, Arizona | Phase 3 | 45 |
| Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTNCT07764978 · Gilbert, Arizona | Phase 3 | 45 |
| AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian CancerNCT07218809 · Birmingham, Alabama | Phase 3 | 40 |
| A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes MellitusNCT07662109 · Huntsville, Alabama | Phase 3 | 40 |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerNCT06868277 · La Mesa, California | Phase 3 | 39 |
| An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.NCT07357597 · Tucson, Arizona | Phase 4 | 39 |
| Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerNCT06350097 · Fountain Valley, California | Phase 3 | 37 |
| A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)NCT07221253 · Birmingham, Alabama | Phase 3 | 37 |
| AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)NCT05850234 · Birmingham, Alabama | Phase 1/2 | 36 |
| Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaNCT06921785 · Phoenix, Arizona | Phase 3 | 36 |
| A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT06417814 · Fayetteville, Arkansas | Phase 3 | 34 |
| Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA TreatmentNCT06750289 · Chandler, Arizona | Phase 3 | 34 |
| A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background DapagliflozinNCT07662135 · Sun City, Arizona | Phase 3 | 33 |
| A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes MellitusNCT07784725 · Dothan, Alabama | Phase 3 | 33 |
| A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus ErythematosusNCT07430306 · Anniston, Alabama | Phase 3 | 31 |
| A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe AsthmaNCT06023589 · Montgomery, Alabama | Phase 3 | 30 |
| Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)NCT06079671 · Birmingham, Alabama | Phase 3 | 28 |
| A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid ArthritisNCT07276581 · Glendale, Arizona | Phase 2 | 28 |
| A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes MellitusNCT07662044 · Birmingham, Alabama | Phase 3 | 27 |
| AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)NCT07611110 · Dothan, Alabama | Phase 3 | 26 |
| Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerNCT05061550 · Little Rock, Arkansas | Phase 2 | 25 |
| Observational Study Protocol: LIVER-RNCT06252753 · Birmingham, Alabama | — | 24 |
| A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationNCT05877599 · Gilbert, Arizona | Phase 1 | 23 |
| Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHLNCT06526793 · Phoenix, Arizona | Phase 2 | 23 |
| A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes MellitusNCT07776509 · Escondido, California | Phase 3 | 23 |
| An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsNCT05835310 · Phoenix, Arizona | Phase 3 | 22 |
| Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced FibrosisNCT07610837 · Chandler, Arizona | Phase 2 | 20 |
| An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCNCT07720284 · Hot Springs, Arkansas | Phase 3 | 19 |
| Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)NCT05489211 · Los Angeles, California | Phase 2 | 18 |
| Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid TumorsNCT06218914 · Duarte, California | Phase 1 | 18 |
| DESTINY-PANTUMOUR04NCT07124000 · Birmingham, Alabama | — | 18 |
| A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background InsulinNCT07664553 · Little Rock, Arkansas | Phase 3 | 17 |
| A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLENCT06897930 · San Francisco, California | Phase 1/2 | 16 |
| A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With AsthmaNCT07525375 · Bakersfield, California | Phase 2 | 15 |
| A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesNCT05123482 · Duarte, California | Phase 1/2 | 14 |
| Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLNCT05952024 · Berkeley, California | Phase 2 | 14 |
| A Study of Novel Study Interventions and Combinations in Participants With Colorectal CancerNCT06792695 · Scottsdale, Arizona | Phase 2 | 14 |
| Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)NCT07509151 · La Jolla, California | Phase 3 | 14 |
| A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical StudiesNCT07606066 · Peoria, Arizona | — | 14 |
| Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLCNCT04686305 · Duarte, California | Phase 1 | 13 |
| Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsNCT05797168 · Duarte, California | Phase 1/2 | 13 |
| Study of AZD0754 in Participants With Metastatic Prostate CancerNCT06267729 · Duarte, California | Phase 1/2 | 13 |
| A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesNCT06564038 · Boston, Massachusetts | Phase 1/2 | 13 |
| A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)NCT07073547 · Phoenix, Arizona | Phase 1 | 13 |
| AZD0486 as Monotherapy in B-cell Acute Lymphoblastic LeukaemiaNCT06137118 · Birmingham, Alabama | Phase 1/2 | 12 |
| A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate CancerNCT06879041 · Palo Alto, California | Phase 1 | 12 |
| A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerNCT07647328 · Duarte, California | Phase 3 | 12 |
| Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesNCT05417594 · La Jolla, California | Phase 1/2 | 11 |
| Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNCT05702229 · Los Angeles, California | Phase 2 | 11 |
| Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate CancerNCT07181161 · Fayetteville, Arkansas | Phase 1/2 | 11 |
| Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate CancerNCT07590934 · Duarte, California | Phase 1/2 | 11 |
| A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.NCT06542250 · La Jolla, California | Phase 1/2 | 10 |
| A Platform Study in Non-Small Cell Lung Cancer (NSCLC)NCT06996782 · Phoenix, Arizona | Phase 1/2 | 10 |
| A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple MyelomaNCT07681596 · Duarte, California | Phase 1/2 | 10 |
| AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple MyelomaNCT06106945 · Duarte, California | Phase 1/2 | 9 |
| An Open-label Study of AZD0120 in Adults With Multiple SclerosisNCT07224373 · Tucson, Arizona | Phase 1 | 9 |
| A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid TumorsNCT06130553 · San Francisco, California | Phase 1/2 | 8 |
| AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.NCT06137144 · Duarte, California | Phase 1/2 | 8 |
| A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin LymphomaNCT07123454 · Irvine, California | Phase 1/2 | 8 |
| A Study of AZD0120 in Autoimmune DiseasesNCT07295847 · Tucson, Arizona | Phase 1 | 8 |
| A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer DrugsNCT07336446 · Duarte, California | Phase 1/2 | 8 |
| Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued TreatmentNCT07444567 · Aurora, Colorado | Phase 3 | 8 |
| AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2NCT06219941 · Orange, California | Phase 2 | 7 |
| Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid TumorsNCT06535607 · Los Angeles, California | Phase 2 | 7 |
| First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid TumoursNCT06795022 · La Jolla, California | Phase 1/2 | 7 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.NCT06916806 · Anniston, Alabama | Phase 1 | 7 |
| A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaNCT07069712 · Newark, Delaware | Phase 2 | 7 |
| A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)NCT07098338 · Santa Monica, California | Phase 2 | 6 |
| Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic LeukemiaNCT07109219 · Duarte, California | Phase 1/2 | 6 |
| A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsNCT07115043 · Grand Rapids, Michigan | Phase 1/2 | 6 |
| Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX OverexpressionNCT07155226 · Decatur, Illinois | Phase 1/2 | 6 |
| A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate CancerNCT07192614 · Orlando, Florida | Phase 1/2 | 6 |
| A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast CancerNCT07205822 · Largo, Florida | Phase 3 | 6 |
| Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CMNCT07690436 · Palo Alto, California | — | 6 |
| Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± ObinutuzumabNCT07024706 · Boston, Massachusetts | Phase 2 | 5 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional CohortNCT07024823 · Glendale, California | Phase 1 | 5 |
| Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE ParticipantsNCT07201558 · Birmingham, Alabama | Phase 1 | 5 |
| A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsNCT06188520 · St Louis, Missouri | Phase 1/2 | 4 |
| Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid TumoursNCT07446855 · New York, New York | Phase 1/2 | 4 |
| First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate CancerNCT07529717 · Orlando, Florida | Phase 1/2 | 4 |
| A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234NCT07546760 · Chandler, Arizona | Phase 1 | 4 |
| Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid TumorsNCT06005493 · Jacksonville, Florida | Phase 1/2 | 3 |
| Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart FailureNCT06651970 · Charlotte, North Carolina | Phase 4 | 3 |
| A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)NCT07064122 · Miami, Florida | Phase 1 | 3 |
| A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care TherapyNCT07161414 · Huntersville, North Carolina | Phase 1 | 3 |
| Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerNCT07427394 · St Louis, Missouri | Phase 2 | 3 |
| A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic ImpairmentNCT07343960 · Rialto, California | Phase 1 | 2 |
| A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy ParticipantsNCT07723833 · Glendale, California | Phase 1 | 2 |
| Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab UsersNCT06594068 · Las Vegas, Nevada | Phase 4 | 1 |
| Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab UsersNCT06659029 · Wilmington, North Carolina | — | 1 |
| Tezspire Cardiac Events PASSNCT06951867 · Wilmington, Delaware | — | 1 |
| Anifrolumab Pregnancy StudyNCT07049653 · Cary, North Carolina | — | 1 |